NCT07069062View on ClinicalTrials.gov

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

May 31, 2027

Conditions
Solid Tumor
Interventions
DRUG

Test product HY0001a for injection

HY0010a for injection should be administered at the recommended dosage

Trial Locations (1)

100143

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Sichuan Huiyu Pharmaceutical Co., Ltd

INDUSTRY